Published in:
05-07-2023 | Pathology | Original Article
High Proportions of Newly Detected Visible Lesions and Pathology Grade Change Among Patients with Barrett’s Esophagus Referred to Expert Centers
Published in: Digestive Diseases and Sciences | Issue 9/2023
Login to get accessAbstract
Background and Aims
Endoscopic eradication therapy for Barrett’s esophagus (BE)-related neoplasia is increasingly being performed at tertiary and community centers. While it has been suggested that these patients should be evaluated at expert centers, the impact of this practice has not been evaluated. We aimed to assess the impact of referral of BE-related neoplasia patients to expert centers by assessing the proportion of patients with change in pathological diagnosis and visible lesions detected.
Methods
Multiple databases were searched until December 2021 for studies of patients with BE referred from the community to expert center. The proportions of pathology grade change and newly detected visible lesions at expert centers were pooled using a random-effects model. Subgroup analyses were performed based on baseline histology and other relevant factors.
Results
Twelve studies were included (1630 patients). The pooled proportion of pathology grade change after expert pathologist review was 47% (95% CI 34–59%) overall and 46% (95% CI 31–62%) among patients with baseline low-grade dysplasia. When upper endoscopy was repeated at an expert center, the pooled proportion of pathology grade change was still high 47% (95% 26–69%) overall and 40% (95% CI 34–45%) among patients with baseline LGD. The pooled proportion of newly detected visible lesions was 45% (95% CI 28–63%) and among patients referred with LGD was 27% (95% CI 22–32%).
Conclusion
An alarmingly high proportion of newly detected visible lesions and pathology grade change were found when patients were referred to expert centers supporting the need for centralized care for BE-related neoplasia patients.